Soluble molecules and bone metabolism in multiple myeloma: A review

Gabriele Zoppoli, Enrico Balleari, Riccardo Ghio

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Bone metabolism and turnover are strongly altered in multiple myeloma, as a consequence of the proliferation of malignant cells resembling plasmacells in the bone marrow. By both direct or indirect secretion of several molecules, and cell-to-cell interactions, multiple myeloma cells lead to severe and disabling skeletal alterations, such as osteolytic lesions, pathologic fractures, and osteoporosis. In this review, we summarize the studies concerning the soluble molecules which are supposed to have a role in this pathological process. We then consider the substances that, either in serum or urine specimens, can be dosed in the affected patients, thus giving an indirect measure of their altered bone turnover. In the last part of our review, we discuss the potential action of the new anti-myeloma drug bortezomib (Velcade®, Janssen-Cilag), in opposing and maybe reverting, through a possible direct "pro- osteoblastic" effect, the deranged bone turnover which characterizes this disabling and unavoidably deathly disease.

Original languageEnglish
Pages (from-to)67-70
Number of pages4
JournalClinical Cases in Mineral and Bone Metabolism
Volume5
Issue number1
Publication statusPublished - Jan 2008

Fingerprint

Bone Remodeling
Multiple Myeloma
Bone and Bones
Spontaneous Fractures
Pathologic Processes
Cell Communication
Action Potentials
Osteoporosis
Bone Marrow
Cell Proliferation
Urine
Serum
Pharmaceutical Preparations
Bortezomib

Keywords

  • Bone
  • Bortezomib
  • Multiple myeloma
  • Soluble
  • Turnover

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism
  • Internal Medicine

Cite this

Soluble molecules and bone metabolism in multiple myeloma : A review. / Zoppoli, Gabriele; Balleari, Enrico; Ghio, Riccardo.

In: Clinical Cases in Mineral and Bone Metabolism, Vol. 5, No. 1, 01.2008, p. 67-70.

Research output: Contribution to journalArticle

@article{522952e73eac4edbbe856ef5dbfd5d96,
title = "Soluble molecules and bone metabolism in multiple myeloma: A review",
abstract = "Bone metabolism and turnover are strongly altered in multiple myeloma, as a consequence of the proliferation of malignant cells resembling plasmacells in the bone marrow. By both direct or indirect secretion of several molecules, and cell-to-cell interactions, multiple myeloma cells lead to severe and disabling skeletal alterations, such as osteolytic lesions, pathologic fractures, and osteoporosis. In this review, we summarize the studies concerning the soluble molecules which are supposed to have a role in this pathological process. We then consider the substances that, either in serum or urine specimens, can be dosed in the affected patients, thus giving an indirect measure of their altered bone turnover. In the last part of our review, we discuss the potential action of the new anti-myeloma drug bortezomib (Velcade{\circledR}, Janssen-Cilag), in opposing and maybe reverting, through a possible direct {"}pro- osteoblastic{"} effect, the deranged bone turnover which characterizes this disabling and unavoidably deathly disease.",
keywords = "Bone, Bortezomib, Multiple myeloma, Soluble, Turnover",
author = "Gabriele Zoppoli and Enrico Balleari and Riccardo Ghio",
year = "2008",
month = "1",
language = "English",
volume = "5",
pages = "67--70",
journal = "Clinical Cases in Mineral and Bone Metabolism",
issn = "1724-8914",
publisher = "CIC Edizioni Internazionali s.r.l.",
number = "1",

}

TY - JOUR

T1 - Soluble molecules and bone metabolism in multiple myeloma

T2 - A review

AU - Zoppoli, Gabriele

AU - Balleari, Enrico

AU - Ghio, Riccardo

PY - 2008/1

Y1 - 2008/1

N2 - Bone metabolism and turnover are strongly altered in multiple myeloma, as a consequence of the proliferation of malignant cells resembling plasmacells in the bone marrow. By both direct or indirect secretion of several molecules, and cell-to-cell interactions, multiple myeloma cells lead to severe and disabling skeletal alterations, such as osteolytic lesions, pathologic fractures, and osteoporosis. In this review, we summarize the studies concerning the soluble molecules which are supposed to have a role in this pathological process. We then consider the substances that, either in serum or urine specimens, can be dosed in the affected patients, thus giving an indirect measure of their altered bone turnover. In the last part of our review, we discuss the potential action of the new anti-myeloma drug bortezomib (Velcade®, Janssen-Cilag), in opposing and maybe reverting, through a possible direct "pro- osteoblastic" effect, the deranged bone turnover which characterizes this disabling and unavoidably deathly disease.

AB - Bone metabolism and turnover are strongly altered in multiple myeloma, as a consequence of the proliferation of malignant cells resembling plasmacells in the bone marrow. By both direct or indirect secretion of several molecules, and cell-to-cell interactions, multiple myeloma cells lead to severe and disabling skeletal alterations, such as osteolytic lesions, pathologic fractures, and osteoporosis. In this review, we summarize the studies concerning the soluble molecules which are supposed to have a role in this pathological process. We then consider the substances that, either in serum or urine specimens, can be dosed in the affected patients, thus giving an indirect measure of their altered bone turnover. In the last part of our review, we discuss the potential action of the new anti-myeloma drug bortezomib (Velcade®, Janssen-Cilag), in opposing and maybe reverting, through a possible direct "pro- osteoblastic" effect, the deranged bone turnover which characterizes this disabling and unavoidably deathly disease.

KW - Bone

KW - Bortezomib

KW - Multiple myeloma

KW - Soluble

KW - Turnover

UR - http://www.scopus.com/inward/record.url?scp=45349089235&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=45349089235&partnerID=8YFLogxK

M3 - Article

C2 - 22460849

AN - SCOPUS:45349089235

VL - 5

SP - 67

EP - 70

JO - Clinical Cases in Mineral and Bone Metabolism

JF - Clinical Cases in Mineral and Bone Metabolism

SN - 1724-8914

IS - 1

ER -